Description
ABT-888 can inhibit PARP-1 and PARP-2 with Ki of 5.2 nM and 2.9 nM, respectively.
Storage
2 years at -20centigrade Powder
Molecular Formula
C13H16N4O
Chemical Name
(R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide
Solubility
DMSO 17 mg/mL Water
In vitro
As a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, ABT-888 can inhibit PARP-1 and PARP-2 with Ki of 5.2 nM and 2.9 nM, respectively.
In vivo
ABT-888 enhanced temozolomide antitumor activity, in a dose-proportional manner with no observed toxicity in the B16F10 syngeneic melanoma model. Treatment with ABT-888 combined with temozolomide resulted in significant survival prolongation. ABT-888significantly enhanced survival in GBM12 when combined with concurrent radiotherapy/temozolomide.
Download Datasheet